Stay updated with breaking news from B Biontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration on Friday authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use in children ages 5 to 11, a major step in making the shots available to school-aged kids by early November.
Fewer than a third of parents plan to vaccinate their children for COVID-19 "right away" once the shots become available to 5- to 11-year-olds, according to a poll released Thursday.
Fewer than a third of parents plan to vaccinate their children for COVID-19 "right away" once the shots become available to 5- to 11-year-olds, according to a poll released Thursday.
A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.
A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.